Pharmaceutical manufacturers
Pharmaceutical manufacturers make active ingredients and turn them into tablets, capsules, liquids, injectables and biologics under validated, tightly regulated conditions. Product harm and recall dominate the account, while clean rooms, solvent processes and long requalification times mean a small fire or contamination event becomes a very large loss.
Where losses come from.
- 01
Injury from side effects, contamination, wrong strength or mislabeling, often as mass claims
- 02
Smoke, water or microbial contamination of clean rooms and high-value batches
- 03
Long shutdowns while damaged or contaminated lines are rebuilt, revalidated and reapproved
- PropertyProperty: High, 4 of 5; sector average 3.7; all business types 2.9.
- Business interruptionBusiness interruption: High, 4 of 5; sector average 3.5; all business types 2.7.
- Premises liabilityPremises liability: Moderate, 2 of 5; sector average 1.9; all business types 2.7.
- Products and completed workProducts and completed work: Severe, 5 of 5; sector average 3.4; all business types 2.6.
- Workers’ injuryWorkers’ injury: Elevated, 3 of 5; sector average 3.4; all business types 3.0.
- Commercial autoCommercial auto: Moderate, 2 of 5; sector average 2.3; all business types 2.5.
- Crime and theftCrime and theft: Elevated, 3 of 5; sector average 1.9; all business types 2.2.
- Inland marine and equipmentInland marine and equipment: High, 4 of 5; sector average 2.6; all business types 2.6.
- EnvironmentalEnvironmental: Elevated, 3 of 5; sector average 2.8; all business types 2.3.
- Cyber and dataCyber and data: High, 4 of 5; sector average 2.7; all business types 2.7.
- Professional liabilityProfessional liability: Elevated, 3 of 5; sector average 1.5; all business types 2.0.
- Umbrella and excessUmbrella and excess: Severe, 5 of 5; sector average 3.6; all business types 3.6.
- Cell, gene and other biologic therapies move value into small, irreplaceable batches that need frozen storage and spoil after a short outage.
- Active ingredient supply is concentrated in a few overseas regions while governments push local production, adding new plants and startup risk.
- Larger jury awards and mass litigation over widely used drugs raise the severity of product claims and the cost of defending them.
Twelve lines, rated.
Each line shows its rating and the reason for it; open a line for what to watch for and the controls that matter. Ratings are UrbanStat’s own editorial view of a typical business of this type, on a five-step scale. They are a starting point for questions, not a quote, a rate or a statistical measure.
Property
HighSolvent-based synthesis, granulation and coating carry fire and dust explosion hazards, and clean-room stock is written off after slight smoke or water.
Fire, explosion, water and weather damage to buildings, contents and stock.
- Fluid-bed dryers and mills without explosion venting or suppression
- Flammable solvents dispensed inside production suites
- Plastic clean-room panels and ductwork that spread smoke
- Sprinklers throughout, including clean rooms, plenums and solvent stores
- Explosion protection and grounding on dryers, mills and collectors
- Emergency power for cold rooms, freezers and air handling
Business interruption
HighEach line, site and supplier is named in product approvals, so replacing capacity means months of revalidation before a single sale.
How long and how costly a shutdown is.
- Leading product made at one site with no approved alternate
- Active ingredient bought from a single overseas plant
- Sterile filling or freeze-drying lines with long replacement lead times
- Second approved site or contract manufacturer for main products
- Strategic stock of finished goods and key ingredients held elsewhere
- Business continuity plan covering regulatory re-approval steps
Premises liability
ModerateSites are access-controlled with few visitors; off-site exposure comes from solvent or potent compound releases.
Injuries to customers and the public, on site or caused by operations elsewhere.
- Clinical trial units or public tours on the same premises
- Visitor escort rules and scrubbed, monitored process vents
Products and completed work
SevereMedicines act on the body by design, reach huge numbers of patients, and failures bring mass litigation and costly recalls.
Harm caused by what the business sells, serves, makes, installs or repairs.
- Sterile injectables, implants or products for children and pregnancy
- Opioids and other products with pending class litigation
- Nitrosamine or other impurity findings in past batches
- Independent quality unit with authority to reject batches
- Pharmacovigilance system that tracks and reports adverse events
- Supplier audits and identity testing of every incoming ingredient
Workers’ injury
ElevatedOperators are exposed to potent actives, solvents and sensitizers, and packaging lines produce repetitive strain and machinery injuries.
Injuries and illness to employees.
- Hormones, cytotoxics or antibiotics handled outside containment
- Manual scooping and charging of powders
- Isolators and closed transfer for potent compounds
- Exposure monitoring and medical surveillance by compound band
Commercial auto
ModerateProduct ships by specialist carrier; the insured's own driving is mainly sales representatives in company cars.
Owned, hired and employee-driven vehicles, deliveries, customers’ vehicles in care.
- Large field sales forces with high annual mileage
- Driving record checks and telematics for the sales fleet
Crime and theft
ElevatedControlled substances and small, costly finished goods attract diversion by insiders, cargo theft and counterfeiting.
Burglary, robbery, employee dishonesty, cash, payment and invoice fraud.
- Controlled drugs or lifestyle medicines with street value
- Reject and returned product not destroyed under supervision
- Vaults, dual control and reconciled counts for controlled substances
- Serialization and tamper-evident packaging through the supply chain
Inland marine and equipment
HighSingle truckloads carry very high values, many need an unbroken cold chain, and one temperature excursion condemns the whole load.
Property in transit, at job sites or in the insured’s care, and mobile equipment.
- Biologics and vaccines shipped frozen or refrigerated
- Stock held at contract packers, wholesalers and clinical sites
- Validated shippers and data loggers on every temperature-controlled load
- Vetted carriers with secured parking and tracked trailers
Environmental
ElevatedSynthesis uses large solvent volumes and wastewater carries active residues; formulation-only plants are much lighter.
Pollution on or from the site or the work.
- Bulk active ingredient synthesis with solvent tank farms
- Antibiotic or hormone residues in effluent
- Solvent recovery, diked storage and licensed waste incineration
- Effluent pretreatment with monitoring for active residues
Cyber and data
HighBatch records, validated control systems and trial data are digital, and ransomware halts product release and can expose patient data.
Data breaches, ransomware, system outages and attacks on connected equipment.
- Clinical trial or patient support data held on the network
- Legacy validated systems that cannot be patched
- Segmented networks for validated manufacturing systems
- Offline backups of batch records with tested restoration
Professional liability
ElevatedContract development, testing and stability work for other drug owners brings claims when a failed method or study delays a launch.
Loss or injury caused by advice, design, testing, care or another professional service.
- Development and testing services sold to other drug owners
- Release testing done for clients under their approvals
- Quality agreements that set duties and limit liability with each client
- Independent review of methods and study protocols
Umbrella and excess
SevereA single defective drug can injure thousands of patients and bring mass litigation that exhausts any primary limit.
How likely one liability event is to exhaust primary limits.
- Products with large patient populations or long-term daily use
- Promotion that widens use beyond the approved label
- Safety signal reviews by a cross-functional committee
- Agreements that allocate liability with partners and distributors
Construction, occupancy, protection, exposure.
What a risk engineer expects to find at a typical site of this type, and what to compare a submission against.
- Construction
- Modern noncombustible buildings with clean-room suites, service floors between levels and large air handling plant, alongside older multi-story synthesis blocks and high-bay warehouses.
- Occupancy
- Solvent-based synthesis, powder milling, granulation, drying and coating, aseptic filling and freeze-drying, with cold rooms and warehouses holding very high values per pallet.
- Protection
- Sprinklers through clean rooms, voids and solvent stores, explosion protection on dust equipment, monitored cold storage, backup power, and access control for controlled substances.
- Exposure
- Plants often cluster in business parks with contract packers and suppliers, so one storm, outage or neighbor's fire can stop several links of the supply chain.
What to ask and look for.
Start with the desk review before quoting, then walk the site. Tick questions off as you go; ticks are kept in this browser only.
Before quoting: ask the broker or owner
Documents to request
On site: production and quality
On site: site and protection
On site: supply and continuity
On site: security and people
Refer or decline if you find
- Open regulatory warning or import restriction on the site
- Sterile products made in facilities with repeated contamination findings
- Unsprinklered clean rooms or solvent stores
- Main product reliant on one unaudited ingredient supplier
- Controlled substance counts that do not reconcile
How UrbanStat data helps.
A long power outage after a storm spoils refrigerated stock and breaks clean-room conditions even with no physical damage. Flood or earthquake damage to validated suites means rebuilding and requalifying, not simply drying out.
- Flood scores at the address show whether ground-floor clean rooms, utility plant and cold stores are exposed to water before interruption limits are set.
- Street-by-street exposure views reveal accumulation where a manufacturer, its contract packer and its distributor sit in the same business park, with alerts at a set threshold.
- Live hurricane tracks over insured locations show which plants and cold-chain warehouses face extended power loss as a storm approaches.
What the published numbers say.
Official statistics for the industry or property type closest to this business. They describe the industry as a whole, not any one insured.
1.4 recordable injuries and illnesses per 100 full-time workers, below the private-industry average of 2.3.
0.4 of these cases per 100 workers involved days away from work.
United States, 2024. Industry: Pharmaceutical preparation manufacturing (NAICS 325412). Source: U.S. Bureau of Labor Statistics, Survey of Occupational Injuries and Illnesses, Table 1: incidence rates of nonfatal occupational injuries and illnesses by industry and case types, 2024.
2 fatal work injuries in 2024.
Deaths per 100,000 full-time equivalent workers, for the industry sector as a whole.
United States, private industry, 2024. Industry: Pharmaceutical and Medicine Manufacturing (NAICS 32541), the closest published group. Source: U.S. Bureau of Labor Statistics, Census of Fatal Occupational Injuries; sector rates.
81 citations from 31 inspections; 65% were classed serious, willful or repeat.
- 1910.134 Respiratory protection11
- 1910.1200 Hazard communication9
- 1910.147 The control of hazardous energy (lockout/tagout)7
- 1910.178 Powered industrial trucks5
- 1910.1450 Occupational exposure to hazardous chemicals in laboratories5
Standards cited most often in this industry, by number of citations.
United States, citations issued October 2024 to September 2025 (federal fiscal year 2025). Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412). Covers federal and state-plan inspections. A citation is one violation item; one inspection can produce several. Source: U.S. Department of Labor, Occupational Safety and Health Administration, OSHA enforcement data (inspections and violations); standard titles from the Code of Federal Regulations, Title 29 (section headings).
7,966 fires a year reported in industrial and manufacturing properties, causing about $810 million in direct property damage a year.
United States, 2020 to 2024, annual average. The group includes utility, defense, agriculture and mining properties. Source: National Fire Protection Association, Structure Fires in Industrial and Manufacturing Properties.
88 facilities reported toxic chemical releases totaling 2.3 million pounds on and off site.
- Ammonia621,492
- Methanol435,476
- Dichloromethane311,971
Chemicals released in the largest amounts, in pounds. 41 of the facilities reported at least one chemical classed as a carcinogen.
United States, 2024. Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412). Covers facilities in listed industries with ten or more full-time employees that handle listed chemicals above set thresholds. Source: U.S. Environmental Protection Agency, Toxics Release Inventory basic data files.
Industry loss ratios by line2020 to 2024, the same table on every guide
Loss ratios are published by line of insurance, not by business type. They show how each line has run for insurers as a whole, whatever the business insured.
| Published line | Closest line in this guide | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fire | Property | 63.2% | 67.3% | 62.4% | 45.5% | 40.9% |
| Commercial multiple peril | Property and liability sold as a package | 61.2% | 60.2% | 59.4% | 61.2% | 54.4% |
| Inland marine | Inland marine and equipment | 64.5% | 49.4% | 47.1% | 44.1% | 44.0% |
| Other liability | Premises liability, and most umbrella, professional (other than medical) and cyber cover | 65.1% | 58.8% | 61.0% | 63.7% | 71.2% |
| Products liability | Products and completed work | 48.2% | 52.2% | 46.0% | 57.5% | 60.3% |
| Workers’ compensation | Workers’ injury | 47.9% | 49.2% | 45.0% | 44.3% | 46.0% |
| Commercial auto liability | Commercial auto | 68.3% | 66.5% | 71.9% | 76.8% | 77.6% |
| Commercial auto physical damage | Commercial auto | 50.9% | 56.3% | 64.3% | 65.1% | 57.9% |
United States. Losses incurred as a percent of direct premiums earned, countrywide, before reinsurance and not including loss adjustment expense. Source: National Association of Insurance Commissioners, Report on Profitability by Line by State in 2024, ten-year summary.
- Product recall
- Medicine recalls reach wholesalers, pharmacies and patients in many markets, and general liability excludes the cost of withdrawal.
- Clinical trials liability
- Trial participants injured by an investigational drug need cover that product liability forms often exclude.
- Stock throughput
- Finished goods move through contract packers, warehouses and cold-chain carriers with very high values at each stop.
- Equipment breakdown
- Freeze dryers, chillers and air handlers fail without fire, and validated replacements take months.
| System | Code | Industry |
|---|---|---|
| NAICS 2022, primary | 325412 | Pharmaceutical Preparation Manufacturing |
| NAICS 2022 | 325411 | Medicinal and Botanical Manufacturing |
| NAICS 2022 | 325414 | Biological Product (except Diagnostic) Manufacturing |
| NAICS 2022 | 325413 | In-Vitro Diagnostic Substance Manufacturing |
| SIC 1987, primary | 2834 | Pharmaceutical Preparations |
| SIC 1987 | 2833 | Medicinal Chemicals and Botanical Products |
| SIC 1987 | 2836 | Biological Products, Except Diagnostic Substances |
| SIC 1987 | 2835 | In Vitro and In Vivo Diagnostic Substances |
See this risk on the map.
Book a 30-minute walkthrough tailored to your portfolio and perils of interest.